Metabolomics Signatures of a Respiratory Tract Infection During an Altitude Training Camp in Elite Rowers.

Publication date: Jun 17, 2025

Background: Respiratory pathologies, such as COVID-19 and bronchitis, pose significant challenges for high-level athletes, particularly during demanding altitude training camps. Metabolomics offers a promising approach for early detection of such pathologies, potentially minimizing their impact on performance. This study investigates the metabolic differences between athletes with and without respiratory illnesses during an altitude training camp using urine samples and multivariate analysis. Methods: Twenty-seven elite rowers (15 males, 12 females) participated in a 12-day altitude training camp at 1850 m. Urine samples were collected daily, with nine athletes developing respiratory pathologies (8 COVID-19, 1 bronchitis). Nuclear Magnetic Resonance spectroscopy was used to analyze the samples, followed by data processing with Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA), allowing to use Variable Importance in Projection (VIP) scores to identify key metabolites contributing to group separation. Results: The PLS-DA model for respiratory illness showed good performance (R = 0. 89, Q = 0. 35, p < 0. 05). Models for altitude training achieved higher predictive power (Q = 0. 51 and 0. 72, respectively). Metabolites kynurenine, N-methylnicotinamide, pyroglutamate, propionate, N-formyltryptophan, tryptophan and glucose were significantly highlighted in case of respiratory illness while trigonelline, 3-hydroxyphenylacetate, glutamate, creatine, citrate, urea, o-hydroxyhippurate, creatinine, hippurate and alanine were correlated to effort in altitude. This distinction confirms that respiratory illness induces a unique metabolic profile, clearly separable from hypoxia and training-induced adaptations. Conclusions: This study highlights the utility of metabolomics in identifying biomarkers of respiratory pathologies in athletes during altitude training, offering the potential for improved monitoring and intervention strategies. These findings could enhance athlete health management, reducing the impact of illness on performance during critical training periods. Further research with larger cohorts is warranted to confirm these results and explore targeted interventions.

Open Access PDF

Concepts Keywords
Bronchitis altitude training
Daily athlete health
Nuclear metabolomics
Rowers NMR
Vip PLS-DA
respiratory pathology

Semantics

Type Source Name
disease MESH Respiratory Tract Infection
drug DRUGBANK Cyclic Adenosine Monophosphate
disease MESH COVID-19
disease MESH bronchitis
drug DRUGBANK Pidolic Acid
disease MESH tryptophan
drug DRUGBANK L-Tryptophan
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Creatine
drug DRUGBANK Urea
drug DRUGBANK Creatinine
drug DRUGBANK L-Alanine
disease MESH hypoxia
disease IDO intervention
drug DRUGBANK Oxygen
disease MESH physiological stress
disease MESH depression
disease IDO susceptibility
disease MESH infections
disease MESH sleep deprivation
disease MESH lifestyle factors
pathway KEGG Metabolic pathways
disease MESH respiratory diseases
disease MESH cardiovascular diseases
drug DRUGBANK Etoperidone
disease IDO symptom
disease MESH sore throat
drug DRUGBANK Phosphate ion
drug DRUGBANK Water
disease IDO algorithm
disease IDO infection
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK L-Citrulline
pathway REACTOME Metabolism
disease MESH mountain sickness
drug DRUGBANK Nitrogen
drug DRUGBANK Glutamic Acid
pathway KEGG Nitrogen metabolism
disease MESH oxidative stress
drug DRUGBANK L-Phenylalanine
drug DRUGBANK L-Tyrosine
disease IDO production
drug DRUGBANK Isoxaflutole
disease MESH inflammation
pathway KEGG Tryptophan metabolism
disease MESH viral infections
drug DRUGBANK Nadide
drug DRUGBANK Glutathione
drug DRUGBANK Succinic acid
disease MESH dysbiosis
disease IDO bacteria
drug DRUGBANK Niacin
drug DRUGBANK Coenzyme M
disease MESH privacy
disease MESH Etiology
disease IDO blood
disease MESH Asthma
pathway KEGG Asthma
disease MESH Chronic Obstructive Pulmonary Disease
disease MESH Allergy
disease MESH Pneumonia
drug DRUGBANK Serine
drug DRUGBANK Amino acids
disease MESH Death
pathway REACTOME Immune System
disease IDO cell
pathway REACTOME Fatty acids
disease MESH Aids

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *